After an extended vacay, I'm back. Blimey, Painchek is goddam slow at commercializing.
Sad to say I messed up with the investment in this company, but holding on due to catalysts like FDA could turn things around. In saying that, I would much rather have them be bought out by ResMed, like what happened with Resapp and Pfizer.
$200M market cap if it ever gets there is where I would sell. Management is way too slow in producing results. The revenues are plateauing; funnily enough, Painchek is approaching the total addressable market in Australia ~ $4M p.a. Replicating this internationally requires more resources which they currently don't have.
PainChek General Discussion, page-20299
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.98M | |||
| Open | High | Low | Value | Volume |
| 3.2¢ | 3.3¢ | 3.1¢ | $10.79K | 347.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2502000 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.3¢ | 321501 | 2 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PCK (ASX) Chart |